Universitè De Genève

Universitá Degli Studi Di Milano-Bicocca

Universite Claude Bernard – Lyon1

Universite Claude Bernard—lyon

The Genetics Company, Inc.

Leonardo Scapozza

Peter Gregory Goekjian

Luca Mologni

William Bisson

Shaheen Ahmed

David Gueyrard

Carlo Gambacorti-Passerini

Frank Jaschinski

Barbara Froesch

Benoit Joseph

Florence Popowycz

Pierre Daram

Pierre Garcia

Elena Marzi

Cornelia Marty-Ernst

Guy Lemaillet

Gabriel Garcia

Joseph D'Attoma

Cedric Schneider

Carlo Gambacorti Passerini

Joseph Benoit

Alexandre Orsato

Sébastien Tardy

Margot Boujut

Aurélie Gouiller

Margaux Heritier

David Pejoski

Thibaut De Smedt

The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I): as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

2-acylaminothiazoles for the treatment of cancer

The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

Alpha-carbolines for the treatment of cancer

The present invention relates to compounds of formula (I) 

Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl

The present invention relates to the use of a sulfonamide compound of formula (I): wherein Ris selected from the group consisting of H, CN, halogen, trifluoromethyl, methyl, ethyl, hydroxy, methoxy, ethoxy, morpholino, Ris selected from H, phenyl, substituted phenyl, CN, &#x2014;SOR, wherein R is phenyl or morpholino, &#x2014;NC(O)Me, &#x2014;NC(O)Et, &#x2014;CHC(O)OMe, CHC(O)OEt, Ris selected from the group consisting of H, NO, NH, halogen, &#x2014;COOMe, &#x2014;COOEt, RC(O)N&#x2014;, morpholino, Ris selected from the group consisting of H, a branched or unbranched methyl, ethyl, propyl, butyl, pentyl, methoxy, ethoxy, propoxy, butoxy, a substituted or unsubstituted phenyl, alkinyl, MeSO&#x2014;, COOR, wherein R is a branched or unbranched methyl, ethyl, propyl, butyl, pentyl, -MeOC(O)&#x2014;, a substituted or unsubstituted five or sixmembered aromatic or non-aromatic heterocyclic system with one, two or three heteroatoms, a hetaryl system, a condensed benzoheterocyclic system, X is a linker comprising 2 or 3 atoms, selected from the group consisting of &#x2014;NH&#x2014;NH&#x2014;, &#x2014;NH&#x2014;NH&#x2014;CH2&#x2014;, ethinyl, &#x2014;NH&#x2014;C(O)&#x2014;CH&#x2014;, &#x2014;NH&#x2014;NH&#x2014;SO&#x2014;, &#x2014;C(O)&#x2014;NH&#x2014;CH&#x2014;, &#x2014;NH&#x2014;N&#x2550;CH&#x2014;, &#x2014;NH&#x2014;N&#x2550;C(Me)-, a &#x2014;NH&#x2014;N&#x2550;CH&#x2014; motif being part of a heterocyclic system, preferably a substituted or unsubstituted pyrazole or pyridazine system, and pharmaceutically active salts thereof. Further, the invention relates to the use of these compounds as a medicament, especially for the treatment of cancer. 

Sulfonamides and their use as a medicament

Growing community of inventors

Genève, Switzerland

Leonardo Scapozza